Installer Kaleta App
Accès rapide & mode hors-ligne
Developing new treatments for neglected diseases
The Drugs for Neglected Diseases initiative (DNDi) was founded in 2003 as a collaborative, patient-needs-driven, non-profit drug research and development organization. Headquartered in Geneva, Switzerland, DNDi was established by Médecins Sans Frontières and five public sector research institutions from Brazil, India, Kenya, Malaysia, and France. Its mission is to develop new treatments for neglected diseases, focusing on diseases that disproportionately affect the world’s poorest populations, particularly in Africa, Asia, and Latin America.
DNDi operates with a unique model that leverages partnerships with public and private sectors to deliver affordable treatments. The organization has successfully developed and delivered several new treatments for diseases such as sleeping sickness, leishmaniasis, and Chagas disease, impacting millions of lives. DNDi’s work has significantly contributed to the global health landscape by providing over 40 million treatments to those in need, demonstrating a sustainable and innovative approach to addressing neglected diseases.
DNDi focuses its efforts primarily in regions heavily burdened by neglected diseases, including sub-Saharan Africa, South Asia, and Latin America. The organization has established regional offices and partnerships in key countries such as Kenya, India, and Brazil to facilitate local research and development activities.
DNDi’s flagship programs include the development of new treatments for diseases like sleeping sickness, visceral leishmaniasis, and pediatric HIV. The organization collaborates with various stakeholders to secure funding and resources, ensuring the affordability and accessibility of treatments for affected populations.
DNDi has achieved significant milestones, including the development of six new treatments and the distribution of over 40 million treatments worldwide. Its innovative R&D model has been recognized for its impact on global health, particularly in improving access to essential medicines for neglected populations.
